Parkinson Disease: all 4,583 studies

Page 43 of 46. Open to participants first (1,097), then studies with results posted, then the rest; newest registration first within each.

• Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking LevodopaCompletedNCT00955526Phase 3
• Long-Term Safety Study of KW-6500 in Patients With Parkinson's DiseaseCompletedNCT00955318Phase 3
• A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa TherapyCompletedNCT00955045Phase 2/3
• Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension StudyWithdrawnNCT00947037Phase 2
• Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's DiseaseCompletedNCT00943748Phase 2/3
• Dopaminergic Loss and Pain in Parkinson's DiseaseCompletedNCT00940914Phase 2
• ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease SubjectsCompletedNCT00936676
• Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychometric PropertiesCompletedNCT00932581
• Rajavtihi Neuronal Adult Stem Cells ProjectWithdrawnNCT00927108Phase 2
• Executive Control Analysis in Patients Suffering From Parkinson Disease and Treated by Deep Brain StimulationCompletedNCT00922909Not applicable
• Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s DiseaseWithdrawnNCT00921128Phase 1
• An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's DiseaseCompletedNCT00918177Phase 2
• Development of a Face Valid Executive Functioning TaskCompletedNCT00918112
• Deep Brain Stimulation of the Subthalamic Nucleus (STN) and Cognitive ControlCompletedNCT00917722
• Connecting the Lab to Everyday Life: The Relevance of Executive Dysfunction to Participation and Quality of Life in Parkinson's Disease (PD) Without DementiaCompletedNCT00917280
• An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease SubjectsCompletedNCT00914602Phase 1/2
• Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's DiseaseCompletedNCT00914134Phase 4
• Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II)CompletedNCT00914095Phase 4
• Prospective Memory in Parkinson's DiseaseCompletedNCT00913640
• Prospective Evaluation of Forceplate Measured Levodopa-Induced DyskinesiaCompletedNCT00912977
• Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)Status unknownNCT00909883Phase 3
• The Effects of Vitamin D and Bone Loss in Parkinson's DiseaseCompletedNCT00907972Phase 2
• Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With RamelteonWithdrawnNCT00907595Not applicable
• Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) InhibitorsCompletedNCT00906828Phase 4
• Effects of Chocolate on Motor Symptoms of Parkinson's DiseaseStatus unknownNCT00906763Not applicable
• A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.TerminatedNCT00903838Phase 2
• Olfaction in Patients With Parkinson's Disease Following Treatment With RasagilineCompletedNCT00902941Phase 4
• Anticholinergic Therapy for Overactive Bladder in Parkinson's DiseaseCompletedNCT00892450Not applicable
• Treadmill Training and Quality of Life in Parkinson's DiseaseCompletedNCT00890669Not applicable
• Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa PharmacokineticsCompletedNCT00888186Phase 4
• Deep Brain Stimulation (DBS) For Parkinson's Disease: Caudal Zona Incerta Versus Subthalamic NucleusStatus unknownNCT00888095Not applicable
• Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease PatientsCompletedNCT00888004Phase 2
• Antidepressant Effect of Deep Brain Stimulation in Parkinson's Disease PatientsCompletedNCT00885222Not applicable
• Safety and Tolerability Study of Cogane™ in Healthy Volunteers and Parkinson's Disease PatientsCompletedNCT00875316Phase 1
• Wolff-Parkinson-White Syndrome Anterograde Refractory Period of Accessory DuctTerminatedNCT00873470Not applicable
• Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's DiseaseCompletedNCT00873392Phase 2
• A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric ConditionsCompletedNCT00870974Phase 1
• The Effectiveness of Biofeedback Treatment in Constipated Patients With Idiopathic Parkinson's DiseaseCompletedNCT00869830Not applicable
• Behavioral Therapy to Treat Urinary Incontinence in Parkinson's DiseaseCompletedNCT00866710Not applicable
• A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's DiseaseCompletedNCT00866502Phase 1/2
• Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease PatientsTerminatedNCT00865579Phase 3
• Study of the Application of Magnetic Fields for the Treatment of Parkinson's DiseaseStatus unknownNCT00863226Phase 3
• The Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) Treatment on Motor and Cognitive Measurements in Patients With Parkinson's DiseaseCompletedNCT00858546Not applicable
• Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy BodiesCompletedNCT00855686Phase 4
• Effects of Deep Brain Stimulation in Parkinson's DiseaseStatus unknownNCT00855621Not applicable
• Parkinson's Disease Genetics DatabaseTerminatedNCT00855556
• An Exploratory, Randomized, Blinded, Placebo-Controlled Trial of Folic Acid and L-methylfolate in Parkinson's DiseaseTerminatedNCT00853879Not applicable
• Psychosocial Treatment of Depression in Parkinson's DiseaseStatus unknownNCT00853346Not applicable
• Mapping Mood in the Subthalamic Nucleus in Parkinson's Disease (PD)CompletedNCT00847431
• Expiratory Muscle Training in Patients With Parkinson's DiseaseCompletedNCT00843739Phase 1/2
• Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's DiseaseCompletedNCT00841464
• Trichloroethylene (TCE) Exposure in an Industrial PopulationCompletedNCT00839514
• Botulinum A Toxin in Patients With Parkinson's DiseaseStatus unknownNCT00822913Phase 4
• Pedunculo-Pontin Nucleus (PPN) - Deep Brain Stimulation (DBS) in Gait and Balance Disturbance in Parkinson's Disease (PPN-GAB-PARK Study)Status unknownNCT00821743Phase 1/2
• Effect of Robot-assisted Gait Training on Freezing of Gait in Parkinson's DiseaseCompletedNCT00819949Phase 1/2
• Early Parkinson's Disease (PD) Cross-SectionalTerminatedNCT00817453
• Cognitive Behavioral Therapy for Depression in Parkinson's DiseaseTerminatedNCT00810628Not applicable
• Efficacy and Safety Study of Aplindore in Patients With Early Parkinson DiseaseTerminatedNCT00809302Phase 2
• Select Stim: Selective Stimulation of the Subthalamic Nucleus in Parkinson's Disease. "A Feasibility Study"CompletedNCT00807703Not applicable
• Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson DiseaseTerminatedNCT00806468Phase 4
• The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)TerminatedNCT00804479
• WiiMote Game Controller as a Device to Study Movement DisordersTerminatedNCT00802191
• Use of Interventional MRI for Implantation of Deep Brain Stimulator ElectrodesCompletedNCT00792532
• Mechanisms of Fronto-Subcortical Dysfunction: Comparing PD and OCDStatus unknownNCT00790634
• Biomarkers of Risk of Parkinson DiseaseCompletedNCT00775853
• Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian PatientsStatus unknownNCT00767546Phase 1
• Study of Rivastigmine to Treat Parkinsonian Apathy Without DementiaCompletedNCT00767091Phase 3
• The Parkinson's Disease NeuroGenebank at Scripps Clinic RegistryActive, not recruitingNCT00766948
• The Use of Sensory or Motor Cues Using Electrical Stimulation to Reduce Gait Freezing in Patients With Parkinson DiseaseTerminatedNCT00762814Early Phase 1
• Pilot Study of Safety and Efficacy of SpheramineTerminatedNCT00761436Phase 2
• Fipamezole in Neurogenic Orthostatic HypotensionStatus unknownNCT00758849Phase 2
• Comparison of Continuous and Pulsatile Apomorphine in Parkinson's DiseaseWithdrawnNCT00758368Phase 2
• Rasagiline and Apathy in Parkinson's DiseaseCompletedNCT00755027Phase 4
• Non-interventional Observational Study on WHO-5 Questionnaire Application in Parkinson's DiseaseCompletedNCT00752388
• Treadmill and Music Cueing for Gait Training in Mild to Moderate Parkinson's DiseaseCompletedNCT00750945Not applicable
• Effectiveness of an Active Lifestyle Promotion Program for Patients With Parkinson's DiseaseCompletedNCT00748488Phase 3
• Automatic Recognition of Freezing of Gait EpisodesStatus unknownNCT00738075
• Executive, Activities of Daily Living, and Cholinergic Functions in Parkinson's DiseaseCompletedNCT00737217
• Striatal and Extra-striatal Mechanisms of Falling in Parkinson's DiseaseCompletedNCT00736671
• SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)CompletedNCT00727727
• A Randomised Controlled Trial (RCT) to Evaluate Use of an Individual Auditory Cueing Device's (IACD's) on Freezing and Gait in People With Parkinson's Disease (PD)Status unknownNCT00727467Phase 1/2
• SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's DiseaseCompletedNCT00725478
• Bio-Feedback to Improving Stability in Elderly PopulationStatus unknownNCT00716261Not applicable
• The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's DiseaseStatus unknownNCT00696215Phase 4
• Expectation and Response to Levodopa and Acupuncture in Parkinson's DiseaseCompletedNCT00692328Not applicable
• State Dependent Resonance in the BG-cortical LoopsCompletedNCT00683566Not applicable
• P-glycoprotein Function in Brain DiseasesCompletedNCT00677885
• Far Infrared Irradiation for Management and Treating of Parkinson's Disease (PD)Status unknownNCT00674895Phase 1
• A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed ConditionsCompletedNCT00674310Not applicable
• A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted ConditionsCompletedNCT00673088Not applicable
• Pilot Randomized Controlled Trial of Telemedicine for Individuals With Parkinson Disease in a Rural PopulationCompletedNCT00668551
• Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's DiseaseCompletedNCT00666653Phase 1
• Strength Training and Medication Effects in Parkinson Disease Effects on Hypokinesia in Parkinson DiseaseCompletedNCT00665184Not applicable
• Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic NucleusCompletedNCT00664157Not applicable
• Impact of Deep Brain Stimulation of Subthalamic Nucleus on the Hepatic Glucose Production in Parkinson's DiseaseTerminatedNCT00663312Not applicable
• Clinical Trial on the Effectiveness of Herbal Medicinal Mixture in Parkinson DiseaseCompletedNCT00656253Phase 2/3
• Memory Disorders RegistryCompletedNCT00654563
• Diagnostic and Prognostic Biomarkers in Parkinson DiseaseStatus unknownNCT00653783
• Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's DiseaseTerminatedNCT00643890Phase 2
• Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine AgonistCompletedNCT00643045Phase 3

← Parkinson Disease overview